TLDR:
- Datavault AI Secures $1.2B in Bitcoin and Expands Biotech Collaboration with Scilex
- Datavault (DVLT) Closes Bitcoin Financing with Scilex, Unlocking Major Growth
- DVLT Stock Soars After Datavault Closes $1.2B Bitcoin Deal with Scilex
- Datavault AI Strengthens AI-Biotech Ties with Scilex, Gains 1,237 Bitcoin
- Datavault (DVLT) Expands AI Collaboration with Scilex, Secures $10M Upfront Fees
Datavault AI (NASDAQ: DVLT) has successfully closed the second tranche of its strategic equity financing with Scilex Holding Company (NASDAQ: SCLX). The transaction involves the issuance of a pre-funded warrant, exercisable for 263,914,094 shares of Datavault common stock, in exchange for approximately 1,237.6 Bitcoin. The closure follows stockholder approval during Datavault’s annual meeting on November 24, 2025, and enhances the company’s collaboration aimed at driving growth in AI and biotech sectors.
Datavault Secures Bitcoin and Strategic Capital
Datavault AI has now added 1,237.6 Bitcoin to its digital asset reserves. This latest tranche of financing provides the company with immediate strategic capital. In exchange, Datavault granted Scilex a pre-funded warrant exercisable for 263.91 million shares, which will significantly impact the company’s share count once exercised.
The pre-funded warrant provides Scilex with a substantial equity position, further solidifying their partnership. This move follows the previous tranche closed in September 2025, valued at approximately $8 million in Bitcoin. The transaction demonstrates Datavault’s ability to leverage its digital assets as part of its strategic growth.
Licensing Deal Enhances Partnership with Scilex
Datavault and Scilex have expanded their licensing collaboration. The agreement includes $10 million in upfront license fees, payable in four installments through 2026. Additionally, Datavault is eligible for milestone payments of up to $2.55 billion based on Scilex’s sales performance.
This exclusive worldwide license allows Scilex to use Datavault’s AI-driven technology in the biotech and biopharma industries. Scilex plans to use this technology to build a Biotech Exchange platform, opening new opportunities for both companies. The long-term collaboration aims to drive growth in digital assets and supercomputing infrastructure, with a focus on expanding market share in the biotech sector.
Impact on Datavault’s Future Growth and Potential Risks
The recent deal provides Datavault with critical capital to strengthen its digital asset reserves and accelerate infrastructure development. The issuance of a large number of shares raises concerns about dilution, as the pre-funded warrant could significantly increase the company’s outstanding share count. This potential dilution will depend on the timing and extent of the warrant exercise, which will be closely monitored in the coming months.
Both companies have stated their commitment to scaling the partnership through 2026. Key dependencies include the timely receipt of the scheduled upfront license payments and the achievement of significant sales milestones by Scilex. The deal represents a strategic move that could enhance Datavault’s platform and position it for long-term success, contingent on meeting these milestones.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
